• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is CVS Health (CVS) Cheap Following Strong Q2 Earnings And Higher 2026 Guidance?

    Simply Wall St·08/09/2026 04:38:26
    Listen to the news

    Why CVS Health’s latest earnings and guidance matter for stock watchers

    CVS Health (CVS) has drawn fresh attention after strong second quarter 2026 results, a higher full year earnings outlook, and a broad revamp of its GLP 1 focused weight management program.

    For the second quarter ended June 30, 2026, CVS Health reported sales of US$35.1b compared with US$34.2b a year earlier. Revenue for the period was US$106.1b compared with US$98.9b in the prior year quarter.

    Quarterly net income was US$3.0b compared with US$1.0b a year earlier. Basic earnings per share from continuing operations were US$2.33, while diluted EPS from continuing operations were US$2.31, compared with US$0.81 and US$0.80 respectively a year ago.

    Across the first six months of 2026, CVS Health reported sales of US$68.9b compared with US$67.0b for the same period in 2025. Revenue for the six month period was US$206.5b compared with US$193.5b a year earlier.

    Net income for the first half of 2026 was US$5.9b compared with US$2.8b in the prior year period. Basic EPS from continuing operations were US$4.64 and diluted EPS were US$4.61, compared with US$2.22 and US$2.21 respectively a year ago.

    On August 5, 2026, CVS Health also raised its full year 2026 earnings guidance. The company now expects GAAP diluted EPS in a range of US$6.84 to US$7.04, compared with its prior range of US$6.24 to US$6.44.

    Management also guided to total 2026 revenues of at least US$414.0b and net income attributable to CVS Health in a range of US$8.8b to US$9.1b. For investors following CVS Health stock, this guidance update sets a clearer reference point for expectations through year end.

    See our latest analysis for CVS Health.

    At a share price of US$95.70, CVS Health has given investors a year to date share price return of 19.43%, while the 1 year total shareholder return of 50.65% points to solid long term gains. This comes despite a recent 8.11% 30 day share price decline and softer 7 day and 1 day moves, suggesting enthusiasm around earnings, guidance and the GLP 1 program is consolidating rather than accelerating.

    If the renewed focus on health solutions has your attention, this can be a useful moment to look beyond CVS Health and see what else is gaining traction in healthcare related AI. You can broaden your watchlist by checking out our screener of 43 healthcare AI stocks

    After a sharp year to date climb and a recent pullback, CVS Health sits in a grey zone for timing decisions. Does the current price already reflect the earnings reset and GLP 1 story, or not yet?

    Most Popular Narrative: 16.7% Undervalued

    Analysts following CVS Health see more upside than the current $95.70 share price implies, with their fair value estimate anchored at $114.88 using a 7.5% discount rate.

    The rapidly growing senior population and increased prevalence of chronic diseases are associated with sustained demand for CVS Health's prescription services and broader healthcare offerings, as reflected in revenue and prescription volume growth across its segments; these underlying trends are expected to influence CVS's top-line revenue and market presence in coming years.

    Read the complete narrative.

    Want to see what sits behind that fair value for CVS Health? The narrative focuses on revenue trends, margin performance, and an earnings profile that assumes a different profit mix than today.

    Result: Fair Value of $114.88 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you still need to weigh risks for CVS Health, including sustained pressure on pharmacy reimbursement and ongoing margin challenges in its health care delivery and insurance businesses.

    Find out about the key risks to this CVS Health narrative.

    Next Steps

    With both risks and rewards in play for CVS Health, it makes sense to move quickly and review the numbers yourself. To see a concise breakdown of both sides of the story, start with the 4 key rewards and 2 important warning signs

    Looking for more investment ideas beyond CVS Health?

    If CVS Health is already on your radar, this is the right moment to widen your opportunity set with a few focused stock ideas filtered by clear fundamentals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.